Papers of note in Science Translational Medicine 8 (370)

Leslie K. Ferrarelli

doi:10.1126/scisignal.aam6507

This week’s articles highlight advances in treating spinobulbar muscular dystrophy by activating adenylyl cyclase and autoimmune disease by inhibiting protein interactions that mediate T cell signaling.

NEURODEGENERATIVE DISEASE

Purging X-tra protein aggregates

Adenylyl cyclase activating polypeptide modifies androgen receptor phosphorylation and spinal and bulbar muscular atrophy pathogenesis.

AUTOIMMUNITY

Toning down T cell signaling to treat autoimmunity

A novel inhibitor of interactions between signaling proteins in T cells demonstrates promising preventive and therapeutic effects in several models of autoimmune disease.

Highlighted Articles

1. M. J. Polanco,
2. S. Parodi,
3. D. Piol,
4. C. Stack,
5. M. Chivet,
6. A. Contestabile,
7. H. C. Miranda,
8. P. M.-J. Lievens,
9. S. Espinoza,
10. T. Jochum,
11. A. Rocchi,
12. C. Grunseich,
13. R. R. Gainetdinov,
14. A. C. B. Cato,
15. A. P. Lieberman,
16. A. R. La Spada,
17. F. Sambataro,
18. K. H. Fischbeck,
19. I. Gozes,
20. M. Pennuto
, Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Sci. Transl. Med. 8, 370ra181 (2016).
1. A. Borroto,
2. D. Reyes-Garau,
3. M. A. Jiménez,
4. E. Carrasco,
5. B. Moreno,
6. S. Martínez-Pasamar,
7. J. R. Cortés,
8. A. Perona,
9. D. Abia,
10. S. Blanco,
11. M. Fuentes,
12. I. Arellano,
13. J. Lobo,
14. H. Heidarieh,
15. J. Rueda,
16. P. Esteve,
17. D. Cibrián,
18. A. Martinez-Riaño,
19. P. Mendoza,
20. C. Prieto,
21. E. Calleja,
22. C. L. Oeste,
23. A. Orfao,
24. M. Fresno,
25. F. Sánchez-Madrid,
26. A. Alcamí,
27. P. Bovolenta,
28. P. Martín,
29. P. Villoslada,
30. A. Morreale,
31. A. Messeguer,
32. B. Alarcon
, First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci. Transl. Med. 8, 370ra184 (2016).

[1] M. J. Polanco,
S. Parodi,
D. Piol,
C. Stack,
M. Chivet,
A. Contestabile,
H. C. Miranda,
P. M.-J. Lievens,
S. Espinoza,
T. Jochum,
A. Rocchi,
C. Grunseich,
R. R. Gainetdinov,
A. C. B. Cato,
A. P. Lieberman,
A. R. La Spada,
F. Sambataro,
K. H. Fischbeck,
I. Gozes,
M. Pennuto
, Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Sci. Transl. Med. 8, 370ra181 (2016).

[2] M. J. Polanco,

[3] S. Parodi,

[4] D. Piol,

[5] C. Stack,

[6] M. Chivet,

[7] A. Contestabile,

[8] H. C. Miranda,

[9] P. M.-J. Lievens,

[10] S. Espinoza,

[11] T. Jochum,

[12] A. Rocchi,

[13] C. Grunseich,

[14] R. R. Gainetdinov,

[15] A. C. B. Cato,

[16] A. P. Lieberman,

[17] A. R. La Spada,

[18] F. Sambataro,

[19] K. H. Fischbeck,

[20] I. Gozes,

[21] M. Pennuto

[22] A. Borroto,
D. Reyes-Garau,
M. A. Jiménez,
E. Carrasco,
B. Moreno,
S. Martínez-Pasamar,
J. R. Cortés,
A. Perona,
D. Abia,
S. Blanco,
M. Fuentes,
I. Arellano,
J. Lobo,
H. Heidarieh,
J. Rueda,
P. Esteve,
D. Cibrián,
A. Martinez-Riaño,
P. Mendoza,
C. Prieto,
E. Calleja,
C. L. Oeste,
A. Orfao,
M. Fresno,
F. Sánchez-Madrid,
A. Alcamí,
P. Bovolenta,
P. Martín,
P. Villoslada,
A. Morreale,
A. Messeguer,
B. Alarcon
, First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci. Transl. Med. 8, 370ra184 (2016).

[23] A. Borroto,

[24] D. Reyes-Garau,

[25] M. A. Jiménez,

[26] E. Carrasco,

[27] B. Moreno,

[28] S. Martínez-Pasamar,

[29] J. R. Cortés,

[30] A. Perona,

[31] D. Abia,

[32] S. Blanco,

[33] M. Fuentes,

[34] I. Arellano,

[35] J. Lobo,

[36] H. Heidarieh,

[37] J. Rueda,

[38] P. Esteve,

[39] D. Cibrián,

[40] A. Martinez-Riaño,

[41] P. Mendoza,

[42] C. Prieto,

[43] E. Calleja,

[44] C. L. Oeste,

[45] A. Orfao,

[46] M. Fresno,

[47] F. Sánchez-Madrid,

[48] A. Alcamí,

[49] P. Bovolenta,

[50] P. Martín,

[51] P. Villoslada,

[52] A. Morreale,

[53] A. Messeguer,

[54] B. Alarcon

Papers of note in Science Translational Medicine 8 (370)

Highlighted Articles

Science Signaling

Article Tools